gdc

Multiple Myeloma

FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
Bone Marrow Transplants and Oral Health for Patients with Blood Cancers
Oral HealthTransplantsLymphomaLeukemiaMultiple Myeloma
Two oral health experts offer a thorough exploration of bone marrow transplants and how they relate to the mouth, with many tips for maintaining proper oral care during and after a transplant.
Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
In December 2020, the FDA approved Xpovio (selinexor), for use in combination with the proteasome inhibitor Velcade (bortezomib) and the steroid dexamethasone, for the treatment of adults with multiple myeloma who have received at least 1 previous therapy. Xpovio was previously approved for several types of lymphoma.
FDA Approvals, News & UpdatesMultiple Myeloma
Adrug called Blenrep (belantamab mafodotin-blmf) was recently approved by the Food and Drug Administration (FDA) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies (including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent).
Drugs for Multiple Myeloma
Multiple Myeloma
Here are the drugs and financial support services available to patients receiving treatment for Multiple Myeloma.
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
Multiple Myeloma
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Page 1 of 12
Results 1 - 10 of 114

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country